Hazard
134 recalls in our database tag this hazard, drawn from FDA, USDA FSIS, CPSC, and NHTSA source notices.
Hazard tags are short, machine-readable labels we attach to every recall to make cross-cutting queries possible — “all injectable recalls regardless of agency”, “all listeria recalls in California”, “all airbag recalls in 2025”. The tags are extracted from each recall’s source text during the LLM rewrite step and validated against a fixed schema.
A recall can carry multiple tags — a Listeria recall might also be tagged ready-to-eat and undeclared-allergen. Use the full-text search if you want to combine hazard tags with brand or category filters.
Cipla is recalling Lanreotide Injection 120 mg/0.5 mL prefilled syringes supplied with a safety needle, citing lack of assurance of sterility. 54,583 syringes are affected.
GE Healthcare is recalling Omnipaque (iohexol) Injection, 350 mg/mL, over the presence of particulate matter. The action covers 306,810 vials distributed nationwide.
Fresenius Kabi is recalling 0.9% Sodium Chloride Injection, USP supplied in 250 mL freeflex bags under its own label, citing lack of assurance of sterility.
Fresenius Kabi is recalling 0.9% Sodium Chloride Injection, USP in 50 mL presentation, citing lack of assurance of sterility. Two batches are affected.
Fresenius Kabi is recalling 0.45% Sodium Chloride Injection, USP in 250 mL freeflex bags, citing lack of assurance of sterility.
Teva is recalling nine lots of Octreotide Acetate for Injectable Suspension 20 mg after quality system deficiencies were identified during an FDA inspection at the contract manufacturer.
Teva is recalling two lots of Octreotide Acetate for Injectable Suspension 10 mg after quality system deficiencies were identified during an FDA inspection at the contract manufacturer.
Teva is recalling twelve lots of Octreotide Acetate for Injectable Suspension after quality system deficiencies were identified during an FDA inspection at the contract manufacturer.
New Life Pharma is recalling two lots of Semaglutide Injection 2 mg x 10 sterile multi-dose vials for lack of assurance of sterility.
New Life Pharma is recalling one lot of Semaglutide Injection 2 mg sterile multi-dose vials for lack of assurance of sterility.
New Life Pharma is recalling one lot of Tirzepatide Injection 10 mg sterile multi-dose vials for lack of assurance of sterility.
New Life Pharma is recalling one lot of Tirzepatide Injection 15 mg x 4 sterile multi-dose vials for lack of assurance of sterility.
Cipla USA is recalling 15,221 prefilled syringes of Lanreotide Injection, 120 mg/0.5 mL, over the presence of particulate matter.
Novo Nordisk is recalling Wegovy (semaglutide) Injection, 1 mg/0.5 mL prefilled pens, over the presence of particulate matter after hair was found in a prefilled syringe.
Novo Nordisk is recalling Wegovy (semaglutide) Injection, 0.5 mg/0.5 mL prefilled pens, over the presence of particulate matter after hair was found in a prefilled syringe.
Fresenius Kabi is recalling 2,199,850 vials of Famotidine Injection USP after out of limit results were obtained for endotoxin testing. The FDA classified it Class I.
Otsuka ICU Medical is recalling 21,696 containers of Potassium Chloride Injection 20 mEq in 50 mL because the overwrap may state 10 mEq. The FDA classified it Class I.
Otsuka ICU Medical is recalling one lot of Potassium Chloride Injection because the overwrap label may state 10 mEq when the product is 20 mEq. The FDA classified it Class I.
ProRx is recalling 2,649 vials of Semaglutide Injection 2.5 mg/1 mL from one lot for lack of assurance of sterility.
QuVa Pharma is recalling 75,885 syringes of its R.E.C.K. periarticular injection over the presence of particulate matter.
ProRx is recalling 2,761 vials of Tirzepatide Injection 27 mg/3 mL from one lot for lack of assurance of sterility.
ProRx is recalling 11,119 vials of Semaglutide Injection 8 mg/3.2 mL across four lots for lack of assurance of sterility.
ProRx is recalling 2,809 vials of Semaglutide Injection 12.5 mg/5 mL from one lot for lack of assurance of sterility.
ProRx is recalling 8,310 vials of Semaglutide Injection 6 mg/2.4 mL across three lots for lack of assurance of sterility.
ProRx is recalling 2,805 vials of Semaglutide Injection 5 mg/2 mL from one lot for lack of assurance of sterility.